<DOC>
	<DOC>NCT02062905</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis.</brief_summary>
	<brief_title>Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<criteria>be at least 18 years of age of either sex and any race have a positive history of ocular allergies and a positive skin test reaction to a perennial allergen have a calculated bestcorrected visual acuity of 0.7 logMAR or better in each eye as measured using an ETDRS chart have known contraindications or sensitivities to the use of any of the investigational product medication or components have had ocular surgical intervention within three (3) months prior to Visit 1 or during the study and/or a history of refractive surgery within the past 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>